This trial demonstrated that hypophosphatemia is a relatively prevalent side effect of FCM, driven by significant elevations in FGF23 rather than a class or dose impact of intravenous iron. Even with similar dose schedules, FDI has far less of an impact on FGF23 and serum phosphate. The gene discussed is FGF23; the disease is hypophosphatemia.